SCCM Resource Library-Repurposing Host-Directed Therapeutics for COVID-19

Repurposing Host-Directed Therapeutics for COVID-19

Video Transcription

Video Summary

The presentation discusses the exploration and trials involving tocilizumab, an IL-6 receptor inhibitor, for treating severe COVID-19, despite initial safety concerns. Three Roche-sponsored trials—Covactin, Impactin, and Aribdactin—produced mixed results. Impactin showed positive outcomes, reducing the progression to severe illness, albeit without impacting mortality. Notably, the larger U.K.-based Recovery trial demonstrated a significant mortality benefit with tocilizumab. Despite some safety data gaps in Recovery, subsequent meta-analyses confirmed tocilizumab's effectiveness while Roche trials assured its safety, leading to emergency use authorization. The speaker suggested pre-pandemic study infrastructure could improve response efficiency.

Asset Caption

90-Minute Session | Clinical Evidence for Host-Directed Therapeutics

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

tocilizumab

COVID-19

clinical trials

mortality benefit

emergency use authorization

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.